Compare ResMed Inc. (RMD) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs United States Natural Gas Fund — how do they compare? ResMed Inc. trades at $228.11 (market cap $31.89B), while United States Natural Gas Fund trades at $11.12 (market cap $517.27M). The key difference: ResMed Inc. is far larger — about 61.7× United States Natural Gas Fund's market cap, and ResMed Inc. pays a 1.16% dividend while United States Natural Gas Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and United States Natural Gas Fund for 22 Days on average.
| RMD | UNG | |
|---|---|---|
Market Cap | $31.89B | $517.27M |
Volume | 618,314 | 29,485,537 |
Sector | Health | Commodities - Energy |
52-Week High | $277.88 | $16.90 |
52-Week Low | $182.82 | $9.63 |
Typical Hold Time | 51 Days | 22 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
UNG trades at $11.06, up 0.28% with a bullish technical signal from moving averages. The fund reported $65.15M net income for 2024 despite zero revenue, with strong total assets of $790.02M and minimal debt. Recent news highlights natural gas market volatility with record production and geopolitical tensions influencing energy prices.
The outlook is mixed: technical strength and clean balance sheet support stability, but zero revenue and negative cash flow (-$251.70M) pose fundamental risks. Investors face exposure to natural gas price swings and supply-demand imbalances, requiring careful monitoring of energy market developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
